Press Releases

    • March 28, 2019

    Nemaura CEO Provides Update to Shareholders

    Announces SugarBEAT® Awaiting CE Mark Approval; On Track for FDA submission in Q2 2019 Loughborough, England, March 28, 2019...

    Read more
    March 12, 2019

    Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region

    Loughborough, England , March 12, 2019 (GLOBE NEWSWIRE) — Loughborough, England – March 12, 2019 – Nemaura Medical, Inc....

    Read more
    February 12, 2019

    Nemaura Reports Third Quarter 2018 Financial Results

    Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as...

    Read more
    February 11, 2019

    Nemaura Announces Dr. Fred Schaebsdau to Lead Strategy and Business Development

    Dr. Schaebsdau to Advance European Launch of SugarBEAT® Continuous Glucose Monitor   Nemaura Preparing U.S. FDA 510(k) Submission  ...

    Read more
    February 7, 2019

    Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm

    Loughborough, England – February 7, 2019 – Nemaura Medical Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the...

    Read more
    January 17, 2019

    Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor

    Loughborough, England –Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com a medical technology company focused on the development of SugarBEAT® as...

    Read more
    December 21, 2018

    Nemaura Announces Completion of Key Stages of Technical File Review for SugarBEAT® CE Mark Approval

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    Read more
    December 19, 2018

    Nemaura to Host Investor Webinar on December 21 to Provide Update on Recent Developments

    LOUGHBOROUGH, England – Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    Read more
    December 18, 2018

    Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible...

    Read more
    December 18, 2018

    Nemaura Publishes Positive Data from SugarBEAT® FDA Clinical Trial

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...

    Read more